Admission to Trading

Summary by AI ^BETAClose X

Synthomer plc announced the admission of 430,008 further ordinary shares to trading on the London Stock Exchange's Main Market, effective May 8, 2026. These new shares are fully fungible with the existing ordinary shares, bringing the total number of securities in issue to 163,997,629. This admission follows a prior announcement regarding the application for these additional securities.

Disclaimer*

Synthomer PLC

08 May 2026

Synthomer plc
(the "Company")

Notification of Admission of Further Securities to Trading

Further to the Company's announcement on 7 May 2026 of its application for admission of further securities to trading and upon admission of those securities to trading, the following additional information is disclosed in accordance with The Public Offers and Admissions to Trading Regulations 2024 and PRM 1.6.4R:

1	Details of the issuer
a)	Name	Synthomer plc
b)	LEI	213800EHT3TI1KPQQJ56
2	Details of the transferable securities admitted to trading
a)	Name, type and identification code	Ordinary shares ISIN: GB00BNTVWJ75
b)	Regulated market	London Stock Exchange - Main Market
c)	Number of further securities admitted	430,008
d)	Total number of securities in issue following admission	163,997,629
e)	Fungibility	Fully fungible with existing ordinary shares
3	Admission details
a)	Date of admission	8 May 2026
b)	Prospectus information	Prospectus: N/A Supplementary prospectus: N/A
c)	Coverage of notification	All admissions up to and including 8 May 2026

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END